In 884 Chinese adults with young-onset non-type 1 diabetes, a 3-year precision medicine programme (JADE-PRISM) did not reduce diabetes-related complications vs JADE alone (26.3% vs 28.2%; OR 0.908), though more reached three or more treatment targets (23.8% vs 12.2%).
RCTn = 884
Luk et al. Precision Medicine to Redefine Insulin Secretion and Monogenic Diabetes (PRISM): A Randomized Controlled Trial in Chinese Patients With Young-Onset Diabetes